A study to learn how much elinzanetant gets into the blood, how safe it is and how it affects the body after taking single and multiple amounts in healthy subjects

2023-503864-17-00 Protocol 22382 Human pharmacology (Phase I) - Other Ended

Start 20 Sep 2023 · End 23 Feb 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 22382

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 36
Countries 1
Sites 1

Vasomotor Symptoms as a sex hormone-dependent disorder in women and men

Key facts

Sponsor
Bayer Consumer Care AG, Bayer Consumer Care AG, Bayer AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hormonal diseases [C19]
Trial duration
20 Sep 2023 → 23 Feb 2024
Decision date (initial)
2023-08-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Vasomotor Symptoms as a sex hormone-dependent disorder in women and men

VersionLevelCodeTermSystem organ class
20.0 LLT 10067819 Andropausal symptoms 10014698
21.1 PT 10027304 Menopausal symptoms 100000004872
21.0 LLT 10020407 Hot flashes 10047065

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bayer Consumer Care AG

Sponsor organisation
Bayer Consumer Care AG
Address
Peter Merian-Strasse 84
City
Basel
Postcode
4052
Country
Switzerland

Scientific contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Public contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Bayer Consumer Care AG

Sponsor organisation
Bayer Consumer Care AG
Address
Peter Merian-Strasse 84
City
Basel
Postcode
4052
Country
Switzerland

Scientific contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Public contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Bayer AG

Sponsor organisation
Bayer AG
Address
Kaiser-Wilhelm-Allee 1, Wiesdorf Wiesdorf
City
Leverkusen
Postcode
51373
Country
Germany

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 36 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Nuvisan GmbH
Clincal Service, Wegenerstrasse 13, Ludwigsfeld, Neu-Ulm

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2023-09-20 2024-02-23 2023-09-22 2023-11-08

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-16 Germany Acceptable
2023-08-02
2023-08-08
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-10-06 Germany Acceptable
2023-08-02
2023-10-06